Remedy Plan
Manufacturing · Maryland, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
12111 Parklawn Dr Rm 120, Rockville, Mar...Website
www.remedyplan.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Remedy Plan
Remedy Plan Therapeutics is a small molecule therapeutics start-up company transforming the field of NAMPT inhibition, with a pioneering approach that allows for hyperbolic inhibition of NAMPT that is highly tunable. Remedys groundbreaking mechanism of action, which provides NAMPT inhibition without severe on-target toxicity, unlocks opportunities to treat a range of diseases caused by NAMPT dysregulation. The company is advancing a robust pipeline of tunable NAMPT inhibitors, to address solid tumors, hematologic malignancies, obesity, and autoimmune disorders.Explore more
Remedy Plan Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Remedy Plan your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Remedy Plan had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Remedy Plan has new funding data
Website visits: Recent activity has been detected on your website
Check out if Remedy Plan is spiking on competitors!
Earning: See what the market has to say on Remedy Plan recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Remedy Plan
Product Launch: Get notified when Remedy Plan launches new products
Remedy Plan, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Remedy Plan has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Remedy Plan
Find 2 more new buyers
Compare Similar Companies to Remedy Plan
Compare insights from companies similar to Remedy Plan, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Remedy Plan is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Remedy Plan is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Remedy Plan.
Remedy Plan financials insights
Gather financial insights about Remedy Plan, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Other Financing Round
$18M
Remedy Plan Tech Stack
A closer look at the technologies used by Remedy Plan
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Project
Laboratory Operations, Medical Research, Clinical Operations
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Funding
Funding
Remedy Plan News & Media
Remedy Plan Therapeutics Appoints Jotin Marango, M.D., Ph.D., as Chief Financial and Business Officer
GAITHERSBURG, Md., April 08, 2026 (GLOBE NEWSWIRE) -- Remedy Plan Therapeutics, a clinical-stage biotechnology company developing novel therapies that target fundamental metabolic vulnerabilities in disease, today announced the appointment of Jotin Marango, M.D., Ph.D., as Chief Financial and Business Officer (CFO & CBO).Remedy Plan Therapeutics to Present Results from Phase 1 Healthy Volunteer Study of NAMPT Inhibitor RPT1G and Other Progress at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition
NAMPT inhibitor RPT1G demonstrated favorable safety and significant target engagement in first-in-human studyRemedy Plan Therapeutics Advances RPT1G for Myeloid Cancer Patients with Phase 1 Safety Data and IND Approval
GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- RPT1G, a revolutionary new NAMPT inhibitor developed by Remedy Plan Therapeutics (RPT), was found to be safe and well-tolerated in a Phase 1 study in healthy volunteers at single and multiple ascending dose levels. NAMPT target engagement was seen at every dose level and predicted clinical efficacy against blood cancers.Remedy Plan Therapeutics Raises $18 Million Financing to Accelerate Advancement of Lead Asset RPT1G into Phase 1/2 Trials
Remedy Plan has raised an $18M insider round to advance their lead asset, RPT1G, into a Phase 1/2 clinical trial in patients with AML and high-risk MDS
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Remedy Plan
Sign Up For FreeTo access detailed company insights
Remedy Plan Therapeutics is a small molecule therapeutics start-up company transforming the field of NAMPT inhibition, with a pioneering approach that allows for hyperbolic inhibition of NAMPT that is highly tunable. Remedys groundbreaking mechanism of action, which provides NAMPT inhibition without severe on-target toxicity, unlocks opportunities... Read More
